Clinical use of Omegaven for intestinal failure-associated liver disease(IFALD) and parenteral nutrition associated cholestasis(PNAC)

Clinical use of Omegaven for intestinal failure-associated liver disease(IFALD) and parenteral nutrition associated cholestasis(PNAC) - Clinical use of Omegaven for neonates

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024583

Enrollment

Registered

2016-11-01

Start date

2016-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal failure-associated liver disease and parenteral nutrition-associated cholestasis

Interventions

intravenous administration of OMEGAVEN (fish oil)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients admitted to our hospital suffered from IFALD or PNAC with direct bilirubin>2mg/dl

Exclusion criteria

Exclusion criteria: 1. The case with a side effect (hemolysis and hepatic fibrosis ,etc) 2. The case who dose not improve cholestasis for 3 month 3. The rejection for this study from a patient or his family

Design outcomes

Primary

Measure	Time frame
Improvement of liver dysfunction	—

Countries

Japan

Contacts

Public ContactKen Nagaya

Asahikawa Medical University Department of Pediatrics

nagaya5p@asahikawa-med.ac.jp0166-68-2481

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026